EGFR and non-small cell lung carcinoma: In the phase 2 APPLE trial [52], the utility of longitudinal plasma EGFR T790M monitoring for optimizing the sequencing of gefitinib and osimertinib in patients with advanced EGFR-mutant non-small-cell lung cancer was assessed.